| Project/Area Number |
20730165
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Applied economics
|
|---|
| Research Institution | Tokyo Keizai University |
|---|
Principal Investigator |
NAKAMURA Tsuyoshi Tokyo Keizai University, 経済学部, 准教授 (60323812)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2009: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2008: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Keywords | イノベーション / ミクロデータ / 医薬品産業 / 経済制度 / 企業の異質性 / 研究開発の生産性 / 共同研究開発 / 製品市場における競争 / 技術情報のスピルオーバー / 薬価制度 / イノベーションのインセンティブ / 研究開発形態の選択 |
|---|
| Research Abstract |
In 1998, the Japanese system of reviewing new ethical drugs has drastically changed in favor of exploiting the results from clinical trials conducted abroad. After this institutional change, foreign companies, who can conduct clinical trials abroad in advance, became less dependent on cooperative development with Japanese pharmaceutical companies. Success probability of cooperative drug development is higher when foreign companies participated in the project. This higher rate of success is mainly due to their appropriate choice of cooperating partners, rather than their advantage that they can get a head start by finalizing clinical trials abroad in advance.
|
